Galapagos « Terug naar discussie overzicht

quote:

NielsjeB schreef op 25 september 2015 13:19:

ABBVIE TO ADVANCE ONCE-DAILY ABT-494 TO PHASE 3 IN RHEUMATOID ARTHRITIS BY YEAR-END

- ABBVIE TO OPT-OUT OF COLLABORATION WITH GALAPAGOS ON FILGOTINIB

Sep 25, 2015

NORTH CHICAGO, Ill., Sept. 25, 2015 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis. Following a thorough review of available data, AbbVie will not exercise its right to in-license the Galapagos JAK1 inhibitor, filgotinib.

"We believe ABT-494 has the potential to become a best-in-class therapy for patients," said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "In our view, ABT-494 also offers a faster path to Phase 3 development with less uncertainty."

Per the terms of the agreement with Galapagos, all rights to filgotinib will revert solely to Galapagos.

quote:

_Giulietta_ schreef op 25 september 2015 13:39:

Het blijft natuurlijk een zeer pijnlijke -, maar we herstellen toch gewoon weer even zo'n 20% vanaf DL, dat is toch ook niet bepaald niets.